Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients
Completed
- Conditions
- Diabetes Mellitus, Type II
- Registration Number
- NCT00649909
- Lead Sponsor
- Hadassah Medical Organization
- Brief Summary
The efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes.
We will perform an observational study where we follow up patients with uncontrolled type 2 Diabetes Mellitus and low response to aspirin (Aspirin Resistance), during a period of 6 months in the diabetic clinic. Our hypothesis is that glucose control will improve the response to aspirin in those patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
- Acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable angina pectoris), or revascularization by PCI or by-pass surgery within the last 6 months.
- Acute kidney disease or chronic kidney disease with creatinine clearance <30.
- Acute liver disease or chronic liver disease with severe liver impairment.
- Need for treatment with anticoagulants, clopidogrel, NSAID's, or thiazolidinediones.
- Thrombocytopenia (platelet count <150 x 109/L)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The outcome measure is the laboratory Aspirin Resistance. 3 and 6 months.
- Secondary Outcome Measures
Name Time Method To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors. On screening visit.
Trial Locations
- Locations (1)
Hadassah Medical Organization
🇮🇱Jerusalem, Israel